Skip to main content
Chiome Bioscience Inc. logo

Chiome Bioscience Inc. — Investor Relations & Filings

Ticker · 4583 ISIN · JP3205350006 T Professional, scientific and technical activities
Open in API
Filings indexed 72 across all filing types
Latest filing 2026-05-11 Share Issue/Capital Cha…
Country JP Japan
Listing T 4583

About Chiome Bioscience Inc.

https://www.chiome.co.jp/

Chiome Bioscience Inc. is a clinical-stage biotechnology company specializing in the research and development of antibody-based therapeutics. The company leverages its proprietary ADLib® system, an innovative antibody generation technology, to discover and develop fully human monoclonal antibodies. Its primary mission is to address unmet medical needs by creating novel antibody drugs. The company's operations focus on the early stages of the drug discovery and development process, including initial research and early-phase clinical trials.

Recent filings

Filing Released Lang Actions
譲渡制限付株式報酬としての新株式の払込完了に関するお知らせ
Share Issue/Capital Change Classification · 90% confidence The document is a press release announcing completion of payment for newly issued shares as restricted stock compensation, specifying share count, price, total amount, and allocation to directors. This is clearly an announcement of a share issuance/capital change. Therefore it falls under Share Issue/Capital Change (SHA).
2026-05-11 Japanese
第23回新株予約権（行使価額修正条項付）の月間行使状況に関するお知らせ
Regulatory Filings
2026-05-01 Japanese
確認書
Regulatory Filings Classification · 100% confidence The document is titled '確認書' (Confirmation Letter) and explicitly states it is filed under the Financial Instruments and Exchange Act Article 24-4-2. It serves as an officer certification confirming the accuracy of the company's Annual Securities Report (有価証券報告書). According to the 'CERTIFICATION RULE', documents that are primarily officer certifications or attestations, even if they reference a report, should be classified as Regulatory Filings (RNS) rather than the report itself. FY 2025
2026-03-27 Japanese
有価証券報告書－第22期(2025/01/01－2025/12/31)
Annual Report Classification · 100% confidence The document is a Japanese 'Yuka Shoken Hokokusho' (Securities Report), which is the Japanese equivalent of a 10-K. It contains comprehensive financial statements, business descriptions, and management analysis for the fiscal year ending December 31, 2025. It is a formal regulatory filing submitted to the Kanto Local Finance Bureau. FY 2025
2026-03-27 Japanese
有価証券届出書（組込方式）
Capital/Financing Update Classification · 100% confidence The document is a 'Securities Registration Statement' (有価証券届出書) filed with the Kanto Local Finance Bureau by Chiome Bioscience Inc. It details the issuance of new share acquisition rights (stock options/warrants) and convertible bonds. This type of regulatory filing, which outlines the terms of a capital raise, falls under the 'Capital/Financing Update' category as it describes specific fundraising activities and capital structure changes.
2025-11-28 Japanese
確認書
Report Publication Announcement Classification · 100% confidence The document is a 'Confirmation Letter' (Kakunin-sho) filed under the Financial Instruments and Exchange Act, specifically related to the accuracy of the semi-annual report (第２四半期報告書). While it references the semi-annual report, the document itself is a regulatory filing confirming the validity of the financial statements for the period ending June 30, 2025. Since it is a specific regulatory requirement for filing financial reports in Japan and does not fit into the other categories like 'IR' (which would be the report itself) or 'RPA' (which is an announcement of a report), it is best classified as a Regulatory Filing.
2025-08-12 Japanese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.